Pfizer

Bulgaria will donate 258,570 doses of Comirnaty vaccine from Pfizer/Biontech to Bosnia and Herzegovina, the government decided.

"I hope that another type of vaccine will be developed soon, according to the classic method, long-lasting vaccines, multifactorial, which with one injection will completely protect us from current and future variants of the coronavirus."

This was said on BNR by the infectious disease specialist Prof. Georgi Popov from Sofiamed University Hospital.

Three doses of the Pfizer-BioNTech coronavirus vaccine appear effective against the Omicron variant, a lab test indicated - encouraging news, even as Denmark and Britain announced new restrictions to stem surging caseloads.

COVID vaccination will probably be needed each year. This was stated by the CEO of Pfizer. Scientists believe they have found a link between the appearance of blood clots and the Astra Zeneca vaccine.

The European drug regulator announced on Tuesday that it would approve vaccines adapted to Covid's new version, Omicron, within three to four months if necessary, but existing drugs would continue to provide protection, Reuters reported.

Biontech says it expects to have more data within two weeks to help determine whether the coronavirus vaccine, which it co-developed with Pfizer, needs to be reworked because of a new version of the coronavirus discovered in South Africa.

Pfizer and Biontech have said they expect to be able to deliver a possible new vaccine made for the new version in about 100 days, if necessary.

The Commission for Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EDA) has recommended that the use of the Comirnaty vaccine by Biontech / Pfizer against COVID-19 be given to children aged 5 to 11 years.

The vaccine is already used on children that are 12 years old.

A study published in the British Medical Journal found a gradual increase in the risk of COVID-19 on the 19th day after taking a second dose of the Pfizer / Biontech vaccine against the new coronavirus, Medical Express reported.

On Friday, the EU medicines supervisor said countries could use Merck's covid pill in emergencies caused by the growing number of cases before treatment is officially approved across the bloc.

Pfizer UK managing director Ben Osborne said on Tuesday that the pharmaceutical company's Covid-19 drug, Paxlovid, could be available in the UK "very early in 2022".

Meanwhile, Merck's coronavirus pill, Molnupiravir, will be released as part of a UK trial in late November.